FindTrial
Sign In

Screening of Renal Cancer

Optical Spectroscopy Combined with HPLC-LIF to Differentiate Benign and Malignant Renal Tissues.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/08/027398
Enrollment
105
Registered
2020-08-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C649- Malignant neoplasm of unspecifiedkidney, except renal pelvis

Interventions

None listed

Sponsors

Manipal Academy of Higher Education
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All above 18 years of age and having malignant or benign type of kidney cancer (like clear cell renal cell carcinoma, urothelial carcinoma, chromophobe renal cell carcinoma, oncocytoma,angiomyolipoma and cystic renal cell carcinoma) are included.

Exclusion criteria

Exclusion criteria: All male and female below age 18 are excluded

Design outcomes

Primary

MeasureTime frame
The fluorescence spectroscopy can be very useful to explore the mechanism involved during the progression of renal cancer. Along with multivariate data analysis the fluorescence spectra can give useful information for the objective diagnosis of tissue samples. The Raman spectrum and the HPLC-LIF protein profile can give complementary information of the tissue along with the LIF based diagnosis.Timepoint: 3 years—

Secondary

MeasureTime frame
It can be extended to different type of cancer such as breast cancer.Timepoint: 3 years—

Countries

India

Contacts

Public ContactDr Santhosh Chidangil

Department of Atomic and Molecular Physics, MAHE, Manipal

santhosh.cls@manipal.edu9880092297

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026